179057-18-2

Usage

Uses

Used in Pharmaceutical Industry:
[4-(5-Oxazolyl)phenyl]methanol is used as an active pharmaceutical ingredient for the development of new drugs and medications. Its inherent antibacterial and antifungal properties make it a promising candidate for combating various infections and contributing to the advancement of healthcare solutions.
Used in Organic Synthesis:
In the field of organic synthesis, [4-(5-Oxazolyl)phenyl]methanol is employed as a reagent, playing a crucial role in the synthesis of a wide range of organic compounds. Its unique structure and properties facilitate various chemical reactions, enabling the creation of complex molecules with specific functions and applications.
Used in Chemical Compound Development:
[4-(5-Oxazolyl)phenyl]methanol also serves as a building block in the development of more complex chemical compounds. Its integration into larger molecular structures allows for the design and synthesis of novel materials with diverse applications across different industries, including pharmaceuticals, materials science, and chemical research.

Upstream product

• 1571-08-0 methyl 4-formylbenzoate 
• 179057-14-8 4-oxazol-5-ylbenzoic acid methyl ester 

Downstream Products

• 179055-60-8 Cycloheptyl-(4-oxazol-5-yl-benzyl)-amine 
• 179057-31-9 4-(oxazol-5-yl)benzaldehyde 

Relevant academic research and scientific papers

DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION

To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1) : (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.

Inhibitors of acyl-coA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N- (heteroaryl-substituted benzyl)-N'-arylureas

A series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylurea and related derivatives represented by 2 and 3 have been prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Among these novel compounds, the type 3 series was superior. A pyrazol-3-yl group on the N-benzyl group of this trisubstituted urea (i.e. 3, Ar1 = pyrazol-3- yl) was identified as a heteroaromatic ring providing a good profile of biological activity. As a result of optimization of the combination with the N-alkyl group (R) and N-aryl group (At3), compound 3aq (FR186054) was identified as a new, orally efficacious ACAT inhibitor, which exhibited potent in vitro ACAT inhibitory activity (rabbit intestinal microsomes IC50 = 99 nM) and excellent hypocholesterolemic effects in cholesterol-fed rats, irrespective of administration mode (ED50 = 0.046 mg/kg dosed via the diet, ED50 = 0.44 mg/kg administered by gavage in PEG400 vehicle). Moreover, a toxicological study revealed compound 3aq to be nontoxic to the adrenal glands of dogs when tested at a single dose of 10 mg/kg po.